Document is current
Any future updates will be listed below
-
Authors
McKeigue, Paul M. https://orcid.org/0000-0002-5217-1034
Spiliopoulou, Athina
McGurnaghan, Stuart
Colombo, Marco
Blackbourn, Luke
McDonald, Timothy J.
Onengut-Gomuscu, Suna
Rich, Stephen S.
A. Palmer, Colin N.
McKnight, John A.
J. Strachan, Mark W.
Patrick, Alan W.
Chalmers, John
Lindsay, Robert S.
Petrie, John R.
Thekkepat, Sandeep
Collier, Andrew
MacRury, Sandra
Colhoun, Helen M.
- License Information
-
More Information
Article History
Received: 13 March 2019
Accepted: 15 July 2019
First Online: 23 August 2019
Ethics approval and consent to participate
: The study was carried out in accordance with the ethical principles in the Declaration of Helsinki and was approved by the Tayside Research Ethics Committee (reference 10/S1402/43). Informed consent was obtained from all participants.
: Not applicable.
: HC receives research support and honoraria and is a member of advisory panels or speaker’s bureaus for Sanofi Aventis, Regeneron, Novartis, Novo-Nordisk and Eli Lilly. HC receives or has recently received non-binding research support from Pfizer, AstraZeneca and Novo-Nordisk. HC holds shares in Roche and Bayer. RL receives personal fees and non-financial support from Novo Nordisk, personal fees from Eli Lilly Ltd and non-financial support from Merck Sharp and Dohme. JP receives personal fees from Novo Nordisk, non-financial support from Merck (Germany) and Itamar Medical, personal fees from Lilly, ACI Clinical, Pfizer, Astra Zeneca and grants from Janssen. The other authors declare that they have no competing interests.
